Exemestane is oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women in which there has been progression of the disease after therapy with tamoxifen. It is a member of the class of antiestrogens known as aromatase inhibitors.
It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme, causing its inactivation.
The mechanism of action of exemestane is as an Aromatase Inhibitor.

Sterling holds Certificate of Suitability n. R0-CEP 2017-056-Rev 00 issued by Quality of Medicines & HealthCare (EDQM) on 04/04/2018.

US DMF was submitted to FDA on 21/01/2009 and the following number was assigned n. 22439.

Drug product containing Sterling’s Exemestane is commercialized in Europe and in other Countries.